Li T, Zhang B, Du X, Pei S, Jia Z, Zhao Y
JAMA Netw Open. 2024; 7(8):e2427266.
PMID: 39133484
PMC: 11320166.
DOI: 10.1001/jamanetworkopen.2024.27266.
Seo W, Kim H, Kim J, Min J
Korean J Intern Med. 2024; 39(1):7-24.
PMID: 38225822
PMC: 10790047.
DOI: 10.3904/kjim.2023.395.
du Cros P, Greig J, Alffenaar J, Cross G, Cousins C, Berry C
Int J Tuberc Lung Dis. 2023; 27(12):885-898.
PMID: 38042969
PMC: 10719894.
DOI: 10.5588/ijtld.23.0341.
Dufault S, Crook A, Rolfe K, Phillips P
Stat Med. 2023; 43(3):501-513.
PMID: 38038137
PMC: 7617374.
DOI: 10.1002/sim.9961.
Patil S, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A
Trials. 2023; 24(1):773.
PMID: 38037119
PMC: 10688049.
DOI: 10.1186/s13063-023-07701-6.
Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up.
Sauer S, Mitnick C, Khan U, Hewison C, Bastard M, Holtzman D
Clin Infect Dis. 2023; 78(1):164-171.
PMID: 37773767
PMC: 10810712.
DOI: 10.1093/cid/ciad589.
Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
Kim H, Shin S
Cell Mol Life Sci. 2023; 80(10):291.
PMID: 37704889
PMC: 11072447.
DOI: 10.1007/s00018-023-04914-5.
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis.
Kim H, Lee Y, Song M, Kwon B, Kim Y, Lim S
Sci Rep. 2023; 13(1):11275.
PMID: 37438379
PMC: 10338469.
DOI: 10.1038/s41598-023-38394-1.
Rapid Diagnosis of Recurrent Paucibacillary Tuberculosis.
Jafari C, Olaru I, Daduna F, Lange C, Kalsdorf B
Pathog Immun. 2023; 7(2):189-202.
PMID: 37207169
PMC: 10189871.
DOI: 10.20411/pai.v7i2.565.
Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial.
Liu X, Thompson J, Dong H, Sweeney S, Li X, Yuan Y
Lancet Glob Health. 2023; 11(5):e693-e703.
PMID: 37061308
PMC: 10126227.
DOI: 10.1016/S2214-109X(23)00068-2.
A comparison of clinical development pathways to advance tuberculosis regimen development.
Chang V, Phillips P, Imperial M, Nahid P, Savic R
BMC Infect Dis. 2022; 22(1):920.
PMID: 36494644
PMC: 9733404.
DOI: 10.1186/s12879-022-07846-w.
An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis.
Karanika S, Gordy J, Neupane P, Karantanos T, Castillo J, Quijada D
Front Immunol. 2022; 13:972266.
PMID: 36189260
PMC: 9523784.
DOI: 10.3389/fimmu.2022.972266.
Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study.
Youn H, Shin M, Jeong D, Kim H, Choi H, Kang Y
PLoS One. 2022; 17(6):e0268290.
PMID: 35709199
PMC: 9202932.
DOI: 10.1371/journal.pone.0268290.
Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis.
Goodall R, Sanders K, Bronson G, Gurumurthy M, Torrea G, Meredith S
Trials. 2022; 23(1):474.
PMID: 35672833
PMC: 9171092.
DOI: 10.1186/s13063-022-06397-4.
Cost-effectiveness of a medication event monitoring system for tuberculosis management in Morocco.
Yang J, Kim H, Park S, Sentissi I, Green N, Oh B
PLoS One. 2022; 17(4):e0267292.
PMID: 35439273
PMC: 9017941.
DOI: 10.1371/journal.pone.0267292.
An Update on Tuberculosis Vaccines.
Gopalaswamy R, Subbian S
Methods Mol Biol. 2021; 2410:387-409.
PMID: 34914059
DOI: 10.1007/978-1-0716-1884-4_20.
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M
Trials. 2021; 22(1):651.
PMID: 34563240
PMC: 8465691.
DOI: 10.1186/s13063-021-05491-3.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman S, Nahid P, Kurbatova E, Phillips P, Bryant K, Dooley K
N Engl J Med. 2021; 384(18):1705-1718.
PMID: 33951360
PMC: 8282329.
DOI: 10.1056/NEJMoa2033400.
Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis.
Scriba T, Netea M, Ginsberg A
Semin Immunol. 2020; 50:101431.
PMID: 33279383
PMC: 7786643.
DOI: 10.1016/j.smim.2020.101431.
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis.
Marx F, Cohen T, Menzies N, Salomon J, Theron G, Yaesoubi R
Lancet Glob Health. 2020; 8(9):e1223-e1233.
PMID: 32827484
PMC: 7549318.
DOI: 10.1016/S2214-109X(20)30227-8.